Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 146Gastrointestinal 36Head & Neck 29Genitourinary 26Dermatologic 22Gynecologic 19Breast 19Sarcoma 6Lymphoid 6Other solid neoplasm 5CNS 3Plasma cell 2Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 27Hodgkin Disease 3Breast Neoplasms 3Recurrence 2Ovarian Neoplasms 2Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Chronic 1

Interventions

pembrolizumab 2Trastuzumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Azacitidine 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1saracatinib 1sapanisertib 1relatlimab 1pertuzumab 1pemigatinib 1palbociclib 1osimertinib 1orantinib 1omipalisib 1motexafin gadolinium 1larotrectinib 1ipatasertib 1fludarabine 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1cediranib 1cc-486 1capivasertib 1binimetinib 1adavosertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × pembrolizumab × Plasma cell × Clear all
NCT04354246 2026-05-12

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Compugen Ltd

Phase 1 Completed
94 enrolled
GastrointestinalGynecologicHead & NeckPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Neoplasms, Plasma Cell

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡